Leading private equity firms Blackstone and TPG have struck a deal to take women’s health medtech company Hologic private in a transaction valued at up to $18.3 billion, including contingent incentives tied to performance in its breast health business.
Glimpse:
Under the deal terms, shareholders will receive $76 in cash per share, plus a contingent value right (CVR) of up to $3 per share, payable if Hologic meets certain global revenue targets in its breast health unit in FY 2026–27. The total potential payout is thus $79 per share. The agreement has the backing of Hologic’s board and is expected to close in the first half of 2026, subject to regulatory and shareholder approvals.
Hologic, a U.S.-based medical technology and diagnostics company specializing in women’s health and disease detection, is poised to become privately held following a landmark takeover agreement with private equity titans Blackstone and TPG. The cash-and-CVR transaction is one of the most substantial medtech acquisitions in recent years, with an enterprise value peaking at $18.3 billion when accounting for debt and cash.
Shareholders are to receive $76 in cash for each outstanding share at closing, with an additional non-tradable contingent value right (CVR) worth up to $3 per share. This CVR will be settled in two installments of up to $1.50 each, contingent upon Hologic meeting predetermined global revenue milestones in its breast health business during fiscal years 2026 and 2027. The proposed price represents a ~46 % premium over Hologic’s closing stock price as of May 23, 2025 before speculation of a deal first surfaced.
This acquisition aligns with broader trends of private equity interest in medtech plays, especially those with durable diagnostic revenue streams. Hologic has faced headwinds in its breast imaging division, but strong performance in molecular diagnostics has bolstered investor confidence. By going private, the company could benefit from greater strategic flexibility, fewer public market pressures and the ability to invest more aggressively in innovation without the constraints of quarterly reporting.
Analysts caution, however, that realizing the full potential of this deal will depend on successful execution especially delivering on the CVR targets, navigating regulatory scrutiny (given Hologic’s market position in mammography), and ensuring continuity in R&D and customer trust during the transition.
“With Blackstone and TPG’s backing, we can accelerate growth and deliver advanced medical technologies to women around the world.”
By
HB Team
